Nutshell Therapeutics is pioneering a transformative approach to drug discovery through its AlloStar allosteric drug discovery platform. This platform integrates advanced computational modules and experimental tools, all powered by a proprietary AI algorithm. By leveraging insights from biochemistry and biophysics, Nutshell is capable of identifying a diverse array of drug entities, including protein activators, subtype and mutation-selective small molecules, and modulators of protein-protein interactions. This innovative technology allows for the stabilization of intrinsically disordered proteins, thereby expanding the potential for small molecule innovation in the pharmaceutical landscape.

The company's current pipeline reflects its commitment to addressing challenging therapeutic targets, particularly in oncology. Nutshell is developing several allosteric inhibitors and activators aimed at specific mutations, such as the p53 Y220C allosteric activator for solid tumors. The pipeline also includes various projects targeting metabolic pathways and other disease indications, showcasing the versatility and potential impact of their allosteric modulation strategies. Through these efforts, Nutshell Therapeutics is positioned to redefine the boundaries of drug discovery and development.

China

Nutshell Therapeutics Inc. Inventing small molecule in the realm of drug discovery fostered by protein dynamics. Leveraging our cutting-edge technology based on protein dynamics, Nutshell

Nutshell Therapeutics

Company Details